TD Cowen Boosts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $117.00

Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target increased by equities researchers at TD Cowen from $115.00 to $117.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. TD Cowen’s price objective would suggest a potential upside of 24.18% from the company’s current price.

A number of other research analysts have also weighed in on the stock. Stifel Nicolaus raised their price target on shares of Mirum Pharmaceuticals from $98.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday. Morgan Stanley raised their target price on Mirum Pharmaceuticals from $95.00 to $123.00 and gave the company an “overweight” rating in a research report on Friday, January 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research report on Thursday, January 22nd. Citizens Jmp decreased their price objective on Mirum Pharmaceuticals from $140.00 to $132.00 and set a “market outperform” rating on the stock in a report on Thursday. Finally, Citigroup reaffirmed an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Friday, December 19th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $114.92.

Mirum Pharmaceuticals Price Performance

MIRM traded down $14.40 during trading on Thursday, hitting $94.22. The company’s stock had a trading volume of 1,266,554 shares, compared to its average volume of 770,760. The firm has a market capitalization of $4.84 billion, a price-to-earnings ratio of -108.89 and a beta of 0.49. Mirum Pharmaceuticals has a twelve month low of $36.88 and a twelve month high of $109.28. The business’s fifty day simple moving average is $92.67 and its 200 day simple moving average is $78.81. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). The company had revenue of $148.93 million during the quarter, compared to analyst estimates of $141.78 million. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. Mirum Pharmaceuticals’s revenue was up 49.8% compared to the same quarter last year. During the same period in the prior year, the business posted $1.00 EPS. On average, equities research analysts forecast that Mirum Pharmaceuticals will post -1.43 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Patrick J. Heron acquired 131,425 shares of the company’s stock in a transaction that occurred on Friday, January 23rd. The stock was purchased at an average price of $68.48 per share, with a total value of $8,999,984.00. Following the completion of the acquisition, the director owned 459,010 shares of the company’s stock, valued at $31,433,004.80. This trade represents a 40.12% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Christopher Peetz sold 9,108 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $103.30, for a total transaction of $940,856.40. Following the sale, the chief executive officer owned 160,294 shares of the company’s stock, valued at approximately $16,558,370.20. The trade was a 5.38% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 45,136 shares of company stock worth $4,352,029 over the last quarter. Corporate insiders own 14.36% of the company’s stock.

Institutional Trading of Mirum Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Comerica Bank raised its position in shares of Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after buying an additional 278 shares during the period. AQR Capital Management LLC lifted its stake in shares of Mirum Pharmaceuticals by 307.3% in the 1st quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock valued at $2,211,000 after purchasing an additional 37,028 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Mirum Pharmaceuticals by 7.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock worth $1,176,000 after purchasing an additional 1,720 shares during the period. Caxton Associates LLP acquired a new stake in shares of Mirum Pharmaceuticals during the 1st quarter worth about $217,000. Finally, Empowered Funds LLC raised its holdings in Mirum Pharmaceuticals by 15.4% in the 1st quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock valued at $1,729,000 after buying an additional 5,120 shares during the period.

Mirum Pharmaceuticals News Roundup

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Q4 revenue beat and strong product demand — Mirum reported ~49.8% y/y revenue growth to $148.9M driven by Livmarli and other bile‑acid medicines, beating top‑line estimates and cited by analysts as the main growth driver. Mirum’s Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues
• Positive Sentiment: Analyst upgrade/price‑target lift from Stifel — Stifel raised its price target to $125 and kept a Buy rating, signaling continued analyst confidence in Mirum’s commercial momentum. Stifel Nicolaus price target raise (Benzinga)
• Positive Sentiment: Bullish market commentary — recent articles and transcripts emphasize strong secular growth and positive technical momentum, which can support upside if execution continues. Mirum Pharmaceuticals: Nothing Stops This Train (But The Technicals)
• Neutral Sentiment: RBC reiteration with slight PT cut — RBC trimmed its target from $130 to $128 but maintained an Outperform rating, calling recent weakness a potential buying opportunity. RBC note (StreetInsider)
• Neutral Sentiment: Citizens JMP trims target but stays constructive — target lowered to $132 with a Market Outperform rating, reflecting continued analyst belief in upside despite near‑term volatility. Citizens JMP price target change (Benzinga)
• Neutral Sentiment: FY‑2026 revenue guidance set to $630–$650M — the range overlaps Street estimates but the midpoint (~$640M) is just below some consensus figures, leaving room for debate on beat vs. miss as the year progresses. Business Wire: Q4 results & guidance
• Negative Sentiment: Q4 EPS missed — Mirum reported ($0.11) EPS vs. a $0.02 consensus (miss of $0.13), which pressured sentiment despite the revenue beat; the company still shows negative net margin and ROE metrics. MarketBeat: Q4 EPS miss
• Negative Sentiment: Mixed investor takeaway — the combination of an EPS miss, guidance that isn’t clearly above consensus, and high short‑term volatility likely explains the intraday pullback as investors re‑weigh near‑term profitability vs. longer‑term revenue growth. Zacks: Q4 loss, revenue beat

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.